Latest Advances in Lung Cancer Research

Stepped palliative care for advanced lung cancer improves quality of life by integrating symptom management and emotional support earlier.

Dato-DXd shows promise in treating advanced “HER2-low” lung cancer, slowing progression and potentially extending survival.

Osimertinib significantly extends progression-free survival in stage III EGFR-mutant lung cancer patients. The drug shows promise as a new standard treatment after chemo and radiation, with manageable side effects.

New treatments for lung cancer, including targeted therapies and immunotherapy, are extending lives and offering hope for patients.

Tagrisso significantly improves survival in patients with unresectable stage III EGFR-mutated lung cancer, offering new hope for a longer life.

Study shows telehealth is as effective as in-person visits for palliative care, maintaining quality of life and survival rates while improving access to care for seriously ill patients.

Lorbrena, a new drug targeting a key protein in cancer cells, shows promise in extending survival for non-small cell lung cancer patients.

Non-smoking Asian American and Pacific Islander women face higher lung cancer risks, prompting research into genetic and environmental causes and new treatments.

“Ground-glass opacity” on lung CT scans, a hazy sign of potential cancer, is linked to higher survival rates, emphasizing the importance of early detection.

The Food and Drug Administration on Thursday approved Amgen’s therapy for patients with the most deadly form of lung cancer.

On May 16, 2024, the Food and Drug Administration granted accelerated approval to tarlatamab-dlle (Imdelltra) for extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.